# OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma

> **NCT03429816** · NA · COMPLETED · sponsor: **University Hospital Heidelberg** · enrollment: 120 (actual)

## Conditions studied

- Gastric Neoplasm
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Adenocarcinoma
- Gastric Adenocarcinoma
- Esophageal Neoplasms

## Interventions

- **PROCEDURE:** Biopsy

## Key facts

- **NCT ID:** NCT03429816
- **Lead sponsor:** University Hospital Heidelberg
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-15
- **Primary completion:** 2021-11-01
- **Final completion:** 2023-11-30
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2025-03-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03429816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03429816, "OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03429816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*